

## Editorial

# Links among Excitation/Inhibition Imbalance, Microglia, and Sleep/Circadian Rhythm in Neurodevelopmental Disorders

**Ishizuka K<sup>1</sup> and Inada T<sup>1,2</sup>**<sup>1</sup>Department of Psychiatry, Nagoya University Hospital, Japan<sup>2</sup>Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, Japan**\*Corresponding author:** Toshiya Inada, Department of Psychiatry and Psychobiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya-shi, Aichi 466-8550, Japan**Received:** July 06, 2018; **Accepted:** July 17, 2018;**Published:** July 24, 2018

## Editorial

Neurodevelopmental disorders such as Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia are characterized by strong clinical comorbidity, which implicates a common genetic etiology across these multiple conditions [1]. For example, independent variants in the same gene or genomic region, such as NRXN1 or 16p11.2, may lead to expression of various neurodevelopmental phenotypes, ranging from ASD to ADHD, to schizophrenia, or to no clinical manifestation at all [2-4]. Recent efforts by the National Institute of Mental Health (NIMH) to resume stalled advancements in the treatment of major psychiatric disorders have led to a reconceptualized research strategy, the Research Domain Criteria (RDoC) initiative, which focuses on constructs of psychology and psychopathology delineated by specific neurocircuitry and molecular entities. The strategy promotes the investigation and characterization of these constructs at various levels of analysis from genes to physiology to behavior [5]. Translation of genetic variants into molecular risk mechanisms is important to enable the development of novel therapeutic targets for these multiple disorders.

## Excitation-Inhibition (E/I) Imbalance in Neurodevelopmental Disorders

A tight balance in E/I in synaptic signal transmission is crucial for normal brain development and function. For example, E/I ratios of individual pyramidal cell dendrites in the cultured hippocampal cultures are 2:1 at 14 days and 4:1 at 19 days [6]. Hippocampal parvalbumin and calretinin-positive interneuron subtypes have E/I ratios of 14:1 and 3:1 ratios, respectively [7]. Rubenstein and Merzenich (2003) suggested that neurodevelopmental disorders might reflect an increased E/I ratio, leading to hyper-excitability of cortical circuits [8]. In fact, many genetic variants shared among neurodevelopmental disorders are significantly overrepresented in pathways related to excitatory and inhibitory neurons [9]. Data from clinical and neurobiological studies that investigated E/I

imbalance-related neurodevelopmental disorders have accumulated and support this hypothesis. For example, during early development, the neurotransmitter,  $\gamma$ -Aminobutyric Acid (GABA) is an excitatory transmitter. Disruption in GABAergic function at this stage causes neurodevelopmental disorders including intellectual disability and ASD [10]. In contrast, in adults, GABA is the main inhibitory neurotransmitter in adult. Hypofunction of the N-Methyl-D-Aspartate (NMDA) receptor, possibly in critical inhibitory GABAergic interneurons, may contribute to the pathophysiology of schizophrenia [11,12]. Neurexins and neuroligins, which are trans-synaptic cell-adhesion molecules, are localized at both excitatory and inhibitory synapses and contribute to maintenance of a proper E/I balance at the network level. Disruption of neurexin/neuroligin causes a phenomenon similar to ASD and schizophrenia [10,13,14]. Despite the complexities of defining and measuring the E/I ratio, dysregulation of brain circuits may be an influential mechanism in neurodevelopmental disorders.

## Molecular Mechanisms of E/I Balance Focused on Microglia

Microglia, which are the resident macrophages and phagocytes of the brain, are present from early stages of nervous system development, potentially allowing them to contribute to synaptic deficits and the pathobiology of neurodevelopmental disorders. According to the findings of altered E/I balances shown in animal models of ASD, involves regulation at synaptic or circuit levels [14,15]. Regarding the synaptic E/I balance, microglia contribute to major aspects of the structural shaping and functional modulation of the connectivity in the developing and healthy brain. Even at the circuit level, microglia modulate E/I balance, which involves the interplay between GABAergic interneurons and target pyramidal neurons [16,17]. Microglia releases inflammatory molecules such as interleukins, tumor necrosis factor- $\alpha$ , and reactive oxygen species, which regulate synaptic maturation and plasticity. These factors may induce disease both by impairing synaptic maturation early in development and by being aberrantly released in the adult. Recently, microglia are associated with neuroinflammatory processes in patients with both ASD and schizophrenia [18,19]. A deleterious variant of CX3CR1, which is expressed in microglia only in the brain and encodes a G protein-coupled receptor that binds the chemokine CX3CL1, is associated with increased risk for both ASD and schizophrenia [20]. Transcriptomic studies have identified molecular pathology that is linked to immune system and glia in ASD [21,22]. The activation of excitatory neurons and/or the loss of parvalbumin-positive inhibitory neurons have been observed in mice prenatally exposed to maternal inflammation. Interestingly, a reduction in neural activity rescues the abnormal behavior in offspring affected

by maternal immune activation [23]. Furthermore, comparisons in humans and chimpanzees of genetic structural variations and differences in expression of neural progenitor genes associated with fixed structural variants show a pattern of down-regulation in human radial glial neural progenitors. Compared to chimpanzees, human-specific duplications are associated with up-regulation of genes in human radial glial and excitatory neurons [24]. This finding emphasizes an importance of tightly regulated E/I balance as human being.

## Physiological Mechanisms of E/I Balance Focused on Sleep/Circadian Rhythm

Children and adolescents with ASD suffer from sleep problems, particularly insomnia, at a higher rate (more than 50%) than typically developing children [25,26]. Neurodevelopmental disorders are often concurrent with some form of sleep/circadian rhythm disruption, and increasing evidence suggests a mechanistic overlap between these types of neuropathology and the basic control mechanisms of sleep/circadian timing [27]. The association between clock genes and both ASD and schizophrenia has been suggested [27,28]. Despite the recognition of an association between sleep/circadian rhythm disruption and many neuropsychiatric disorders, mechanistic links remain poorly understood. Interestingly, the cortical E/I ratio is affected by wake/sleep cycles. Recent studies in model animals suggest that sleep homeostasis and circadian processes influence synaptic efficacy and morphology [29,30]. Inhibition of GABAergic transmission within the suprachiasmatic nucleus, where the central circadian clock is located, is important for normal physiological function within the brain. Changes in both GABAergic function during sleep and glutamatergic receptor density following sleep deprivation have been observed [10,31]. The E/I balance may be modified over extended periods of the day-time [32]. Severe circadian timing abnormalities involving desynchronized sleep/wake patterns are observed in schizophrenia [33].

## Future Directions

Although the genetic knowledge of neurodevelopmental disorders has markedly improved, the underlying biological processes are still unclear. Pathogenic mechanisms underlying the E/I imbalance in neurodevelopmental disorders related to both microglia and the sleep/circadian rhythm are more complex than expected. Because sleep/circadian disturbance is one of the most commonly reported signs of many neurodevelopmental disorders, an individual's sleep biology may prove to be a useful phenotype to establish risk factors and markers of disease conditions. Separation of heterogeneous neurodevelopmental disorders into homogeneous subtypes and the use of new technologies such as single-cell whole genome sequencing and patient-derived induced pluripotent stem cell-based models may be necessary for a full understanding of links between a given phenotype and the underlying genetic, cellular, and brain circuit anomalies. Increased understanding of these factors may lead to the ultimate goal of precision medicine for these disorders [34]. Recently, R-baclofen, the selective GABAB receptor agonist, has been suggested to be effective to reduce repetitive behaviors in mouse models of ASD through normalizing the E/I balance [35]. More integrated separation of the E/I balance, microglia, and sleep/circadian rhythm into subgroups of neurodevelopmental disorders could result in a clearer

understanding of the broader neurodevelopmental disorders that are associated with these conditions.

## References

- Jensen M, Girirajan S. Mapping a shared genetic basis for neurodevelopmental disorders. *Genome Medicine*. 2017; 9: 109.
- Lionel AC, Crosbie J, Barbosa N, Goodale T, Thiruvahindrapuram B, Rickaby J, et al. Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. *Science Translational Medicine*. 2011; 3: 95ra75.
- D'Angelo D, Lebon S, Chen Q, Martin-Brevet S, Snyder LG, Hippolyte L, et al. Defining the effect of the 16p11.2 duplication on cognition, behavior, and medical comorbidities. *JAMA Psychiatry*. 2016; 73: 20-30.
- Südhof TC. Synaptic Neurexin Complexes: A Molecular Code for the Logic of Neural Circuits. *Cell*. 2017; 171: 745-769.
- Elmer GI, Brown PL, Shepard PD. Engaging Research Domain Criteria (RDoC): Neurocircuitry in Search of Meaning. *Schizophrenia Bulletin*. 2016; 42: 1090-1095.
- Liu G. Local structural balance and functional interaction of excitatory and inhibitory synapses in hippocampal dendrites. *Nature Neuroscience*. 2004; 7: 373.
- Gulyás AI, Megias M, Emri Z, Freund TF. Total Number and Ratio of Excitatory and Inhibitory Synapses Converging onto Single Interneurons of Different Types in the CA1 Area of the Rat Hippocampus. *The Journal of Neuroscience*. 1999; 19: 10082-10097.
- Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes, Brain and Behavior*. 2003; 2: 255-267.
- Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science*. 2008; 320: 539-543.
- Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. *Biological Psychiatry*. 2013; 73: 161-168.
- Coyle JT. Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. *Cellular and Molecular Neurobiology*. 2006; 26: 363-382.
- Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. *Frontiers in Molecular Neuroscience*. 2008; 1: 6.
- Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. *Nature*. 2008; 455: 903-911.
- Nelson SB, Valakh V. Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. *Neuron*. 2015; 87: 684-698.
- Lee E, Lee J, Kim E. Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders. *Biological Psychiatry*. 2017; 81: 838-847.
- Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic Pruning by Microglia Is Necessary for Normal Brain Development. *Science*. 2011; 333: 1456-1458.
- Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. *Neuron*. 2012; 74: 691-705.
- Takahashi N, Sakurai T. Roles of glial cells in schizophrenia: Possible targets for therapeutic approaches. *Neurobiology of Disease*. 2013; 53: 49-60.
- Chung WS, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in disease? *Nat Neurosci*. 2015; 18: 1539-1545.
- Ishizuka K, Fujita Y, Kawabata T, Kimura H, Iwayama Y, Inada T, et al. Rare genetic variants in CX3CR1 and their contribution to the increased risk of schizophrenia and autism spectrum disorders. *Translational Psychiatry*. 2017; 7: e1184.

21. Ansel A, Rosenzweig JP, Zisman PD, Melamed M, Gesundheit B. Variation in Gene Expression in Autism Spectrum Disorders: An Extensive Review of Transcriptomic Studies. *Front Neurosci.* 2016; 10: 601.
22. Reilly J, Gallagher L, Chen JL, Leader G, Shen S. Bio-collections in autism research. *Mol Autism.* 2017; 8: 34.
23. Shin Yim Y, Park A, Berrios J, Lafourcade M, Pascual LM, Soares N, et al. Reversing behavioural abnormalities in mice exposed to maternal inflammation. *Nature.* 2017; 549: 482-487.
24. Kronenberg ZN, Fiddes IT, Gordon D, Murali S, Cantsilieris S, Meyerson OS, et al. High-resolution comparative analysis of great ape genomes. *Science.* 2018; 360: eaar6343.
25. Paavonen EJ, Vehkalahti K, Vanhala R, von Wendt L, Nieminen-von Wendt T, Aronen ET. Sleep in Children with Asperger Syndrome. *Journal of Autism and Developmental Disorders.* 2008; 38: 41-51.
26. Souders MC, Mason TBA, Valladares O, Bucan M, Levy SE, Mandell DS, et al. Sleep Behaviors and Sleep Quality in Children with Autism Spectrum Disorders. *Sleep.* 2009; 32: 1566-1578.
27. Wulff K, Gatti S, Wettstein JG, Foster RG. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. *Nature Reviews Neuroscience.* 2010; 11: 589-599.
28. Bourgeron T. The possible interplay of synaptic and clock genes in autism spectrum disorders. *Cold Spring Harbor Symposia on Quantitative Biology.* 2007; 72: 645-654.
29. Frank MG, Cantera R. Sleep, clocks, and synaptic plasticity. *Trends in Neurosciences.* 2014; 37: 491-501.
30. Tononi G, Cirelli C. Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. *Neuron.* 2014; 81: 12-34.
31. Cirelli C, Gutierrez CM, Tononi G. Extensive and divergent effects of sleep and wakefulness on brain gene expression. *Neuron.* 2004; 41: 35-43.
32. Farajnia S, van Westering TLE, Meijer JH, Michel S. Seasonal induction of GABAergic excitation in the central mammalian clock. *Proceedings of the National Academy of Sciences.* 2014; 111: 9627-9632.
33. Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM. Sleep and circadian rhythm disruption in schizophrenia. *The British Journal of Psychiatry.* 2012; 200: 308-316.
34. Wang X, Christian KM, Song H, Ming GI. Synaptic dysfunction in complex psychiatric disorders: from genetics to mechanisms. *Genome Medicine.* 2018; 10: 9.
35. Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S, et al. GABA<sub>B</sub> Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism. *Neuropsychopharmacology.* 2015; 40: 2228-2239.